Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Comparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema

10 de novembro de 2026 atualizado por: Halic University

This randomized crossover clinical trial aims to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will receive both treatment approaches in different sequences. Each intervention period will last 4 weeks, with a 2-week washout period between treatments. Manual lymphatic drainage will be applied three times per week during the intervention periods. Assessments will be performed at baseline, week 4, and week 10.

Visão geral do estudo

Status

Inscrevendo-se por convite

Intervenção / Tratamento

Descrição detalhada

This randomized crossover clinical trial was designed to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will be randomly allocated to one of two treatment sequences. In the first 4-week treatment period, one group will receive Kinesio Taping combined with manual lymphatic drainage, while the other group will receive compression bandaging combined with manual lymphatic drainage. Manual lymphatic drainage will be administered three times per week during the intervention periods.

After completion of the first 4-week treatment period, a 2-week washout period will be implemented. Following the washout period, participants will cross over to the alternative intervention for an additional 4 weeks. Participants who initially received Kinesio Taping will subsequently receive compression bandaging, whereas participants who initially received compression bandaging will subsequently receive Kinesio Taping.

Clinical assessments will be performed at baseline, at the end of the first treatment period (week 4), and at the end of the second treatment period (week 10). Upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength will be evaluated at these time points.

The crossover design allows all participants to receive both therapeutic interventions and enables within-participant comparison of the effects of Kinesio Taping and compression bandaging. The 2-week washout period is included to reduce potential carryover effects from the first treatment period before initiation of the second intervention.

Tipo de estudo

Intervencional

Inscrição (Estimado)

44

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Bakırköy
      • Istanbul, Bakırköy, Turquia (Türkiye), 34149
        • Istanbul University Cerrahpaşa Faculty of Medicine Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Diagnosis of lymphedema following breast cancer treatment (confirmed by clinical evaluation or objective measurements).
  • Age between 18 and 75 years (adult participants will be included).
  • Willingness to participate voluntarily in the study and provision of written informed consent.
  • Unilateral lymphedema (to ensure standardization of assessments).
  • Lymphedema in the chronic stage (present for more than 3 months).
  • A stable condition in terms of lymphedema treatment (no other lymphedema treatment received within the last month).
  • Sufficient functional capacity to complete physical assessments and measurements (movement limitations should not be at a level that prevents evaluation).

Exclusion Criteria:

  • History of advanced-stage cancer or active metastatic disease.
  • Presence of severe cardiovascular or respiratory disease (e.g., heart failure, chronic obstructive pulmonary disease).
  • History of diabetic neuropathy or peripheral vascular disease (may affect lymphedema management due to circulatory impairment).
  • Presence of severe skin reactions or dermatological conditions (that compromise skin integrity and prevent tape application).
  • Pregnancy or breastfeeding.
  • History of allergic reactions to kinesio tape or compression bandages.
  • History of lymphatic drainage surgery or other surgical intervention within the past 6 months.
  • Diagnosis of bilateral lymphedema (only unilateral cases will be included to standardize the assessment process).
  • Inability to actively participate in the study due to mental or cognitive impairment.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Kinesiotaping Group

Patients with lymphedema who will receive kinesio taping treatment first, followed by compression bandaging.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

Experimental: Compression Bandaging

Patients with lymphedema who will receive compression bandaging first, followed by kinesio taping treatment.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Upper Extremity Edema
Prazo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Arm circumference measurement was used as an objective indicator of lymphedema severity. Circumferential measurements were obtained using a non-elastic tape measure at standardized anatomical landmarks along the upper extremity. Measurements were taken at fixed intervals (e.g., every 5 cm) starting from the wrist and progressing proximally toward the elbow and upper arm.

Values were recorded in millimeters (mm), with higher circumference values indicating greater edema severity. There is no predefined upper limit for arm circumference; therefore, larger measurements reflect increased fluid accumulation, whereas smaller values indicate reduced edema.

To quantify lymphedema, the difference in circumference between the affected and unaffected extremities was calculated at each measurement point. A greater inter-limb difference represents more severe lymphedema, while a reduction in this difference over time indicates clinical improvement.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Pain Intensity
Prazo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

The Visual Analog Scale (VAS) is a 10-centimeter horizontal line used to assess pain intensity. Scores range from 0 to 10, where 0 indicates no pain and 10 indicates worst imaginable pain. Higher scores indicate greater pain severity.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Shoulder Range of Motion
Prazo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Joint range of motion (ROM) was assessed to evaluate upper-extremity mobility in individuals with lymphedema. Active ROM measurements were obtained using a standard universal goniometer based on anatomical landmarks. Measurements were recorded in degrees (°) for wrist, elbow, forearm, and shoulder movements.

Higher ROM values indicate greater joint mobility and better functional status, whereas lower values reflect movement limitation. As ROM does not have a single fixed maximum value, results were interpreted relative to anatomical normative values and the contralateral limb.

A reduction of ≥10° compared with the unaffected side was considered a clinically meaningful limitation, while an increase toward normal values over time was interpreted as a positive treatment response. Each movement was measured three times, and the mean value was used for analysis. ROM assessments were performed at baseline and after each intervention period.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Upper Extremity Function
Prazo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Upper-extremity functioning was assessed using the Disabilities of the Arm, Shoulder and Hand (QuickDASH) Functioning Scale, a self-reported questionnaire designed to evaluate physical function and symptoms related to upper-limb disorders. The QuickDASH consists of 30 items, each scored on a 5-point Likert scale ranging from 1 (no difficulty) to 5 (unable to perform or extreme difficulty).

Item scores are combined and transformed into a total score ranging from 0 to 100, where 0 indicates no disability and 100 represents the most severe functional limitation. Higher scores therefore reflect worse upper-extremity functioning and greater disability.

A decrease in QuickDASH score over time indicates functional improvement, whereas an increase reflects worsening functional status. The QuickDASH has no absolute clinical cut-off; however, changes of 10-15 points are generally considered clinically meaningful.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Grip Strength
Prazo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Grip strength was assessed using a Jamar hand dynamometer, a widely accepted and reliable instrument for measuring isometric hand grip strength in clinical and research settings. Measurements were recorded in kilograms (kg), with higher values indicating greater muscle strength and better functional capacity, and lower values reflecting reduced grip strength.

Participants were seated in a standardized position with the shoulder adducted and neutrally rotated, the elbow flexed at 90 degrees, the forearm in a neutral position, and the wrist positioned between 0-30° extension and 0-15° ulnar deviation. Participants were instructed to squeeze the dynamometer with maximal effort for a few seconds. Each hand was tested three times, with adequate rest between trials to minimize fatigue, and the mean value was used for analysis.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Seda Yildiz, PhD, Halic University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

8 de fevereiro de 2026

Conclusão Primária (Estimado)

1 de janeiro de 2027

Conclusão do estudo (Estimado)

1 de abril de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

23 de fevereiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de novembro de 2026

Primeira postagem (Real)

5 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de fevereiro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

All data obtained from the assessment scales used in the study will be shared; however, patients' personal information, including names, surnames, and contact details, will be kept confidential. These personal data will only be shared on an individual basis if specifically requested.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • CIF
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever